Clinical Trial Update: Efficacy and Safety Study of TRK-820 to Treat Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating TRK-820 for conventional-treatment-resistant pruritus in patients on hemodialysis has completed, with results summarized for efficacy a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease
• Uremic Pruritus

Drugs mentioned

• TRK-820

Snippet

Sponsor: SK Chemicals Co., Ltd. | Conditions: Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis | Phase 3 | Status: COMPLETED